iRadimed (NASDAQ:IRMD) Director Monty Allen Sells 1,419 Shares

iRadimed Corporation (NASDAQ:IRMD) Director Monty Allen sold 1,419 shares of iRadimed stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $86.41, for a total value of $122,615.79. Following the completion of the transaction, the director owned 19,581 shares of the company’s stock, valued at approximately $1,691,994.21. The trade was a 6.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

iRadimed Trading Up 1.1%

NASDAQ:IRMD opened at $84.40 on Wednesday. The stock has a 50 day moving average of $91.77 and a 200-day moving average of $93.37. The firm has a market capitalization of $1.08 billion, a PE ratio of 47.15 and a beta of 0.89. iRadimed Corporation has a 52 week low of $67.84 and a 52 week high of $107.90.

iRadimed (NASDAQ:IRMD) last announced its quarterly earnings results on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.02. iRadimed had a return on equity of 23.45% and a net margin of 26.70%.The business had revenue of $20.47 million for the quarter, compared to the consensus estimate of $20.35 million. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. As a group, analysts predict that iRadimed Corporation will post 1.98 EPS for the current fiscal year.

iRadimed Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, August 28th. Shareholders of record on Friday, August 14th were paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date was Friday, August 14th. iRadimed’s dividend payout ratio (DPR) is presently 44.69%.

Analyst Ratings Changes

IRMD has been the subject of several recent research reports. Weiss Ratings lowered shares of iRadimed from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, August 3rd. Wall Street Zen downgraded shares of iRadimed from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, iRadimed presently has a consensus rating of “Moderate Buy” and a consensus target price of $120.00.

Institutional Trading of iRadimed

Several large investors have recently added to or reduced their stakes in IRMD. BlackRock Inc. bought a new stake in iRadimed during the 2nd quarter valued at $92,485,000. California State Teachers Retirement System grew its stake in shares of iRadimed by 12,018.2% in the second quarter. California State Teachers Retirement System now owns 954,549 shares of the medical equipment provider’s stock worth $91,217,000 after purchasing an additional 946,672 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of iRadimed by 1.0% during the third quarter. Vanguard Group Inc. now owns 566,507 shares of the medical equipment provider’s stock valued at $40,313,000 after purchasing an additional 5,475 shares during the period. T. Rowe Price Investment Management Inc. raised its stake in shares of iRadimed by 410.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock valued at $24,893,000 after purchasing an additional 205,783 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in iRadimed by 4.2% in the first quarter. Dimensional Fund Advisors LP now owns 226,146 shares of the medical equipment provider’s stock worth $21,768,000 after purchasing an additional 9,017 shares during the period. 92.34% of the stock is currently owned by institutional investors and hedge funds.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.